Contineum Therapeutics (CTNM) Change in Accured Expenses (2023 - 2026)

Contineum Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $768000.0 for Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 852.94% year-over-year to $768000.0; the TTM figure through Jun 2026 stood at -$309000.0 (down 126.19% YoY), while the FY2025 annual figure was -$516000.0, down 122.41% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at $768000.0, up from -$3.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.9 million in Q4 2024, with the low at -$3.5 million in Q1 2026.
• The 4-year median for Change in Accured Expenses is $124500.0 (2025), against an average of $44571.4.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses sank 653.16% in 2025, then soared 852.94% in 2026.
• Contineum Therapeutics' Change in Accured Expenses stood at -$1.6 million in 2023, then surged by 283.05% to $2.9 million in 2024, then slipped by 28.62% to $2.1 million in 2025, then sank by 63.38% to $768000.0 in 2026.
• Business Quant data shows CTNM's Change in Accured Expenses at $768000.0 in Q2 2026, -$3.5 million in Q1 2026, and $2.1 million in Q4 2025.